INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom(TM) Platform
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom(TM) at CGT Catapult

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.